Printed from https://ideas.repec.org/s/spr/drugsa5.html
Content
January 2018, Volume 41, Issue 1
- 125-137 Evaluation of Electronic Healthcare Databases for Post-Marketing Drug Safety Surveillance and Pharmacoepidemiology in China
by Yu Yang & Xiaofeng Zhou & Shuangqing Gao & Hongbo Lin & Yanming Xie & Yuji Feng & Kui Huang & Siyan Zhan - 139-141 The 9th Biennial Conference on Signal Detection and Interpretation in Pharmacovigilance
by Vicki Osborne & Saad A. W. Shakir
December 2017, Volume 40, Issue 12
- 1163-1165 Is Ribavirin Teratogenic in Humans? No Evidence So Far
by Vicente Soriano & Pablo Barreiro - 1167-1170 Safety Concerns with HPV Vaccines Continue to Linger: Are Current Vaccine Pharmacovigilance Practices Sufficient?
by Rebecca E. Chandler - 1171-1198 Neurological Adverse Effects Attributable to β-Lactam Antibiotics: A Literature Review
by Samuel Deshayes & Antoine Coquerel & Renaud Verdon - 1199-1204 Commercial Online Social Network Data and Statin Side-Effect Surveillance: A Pilot Observational Study of Aggregate Mentions on Facebook
by Marco D. Huesch - 1205-1218 The Ribavirin Pregnancy Registry: An Interim Analysis of Potential Teratogenicity at the Mid-Point of Enrollment
by Susan M. Sinclair & Judith K. Jones & Richard K. Miller & Michael F. Greene & Paul Y. Kwo & Willis C. Maddrey - 1219-1229 Suspected Adverse Effects After Human Papillomavirus Vaccination: A Temporal Relationship Between Vaccine Administration and the Appearance of Symptoms in Japan
by Kazuki Ozawa & Akiyo Hineno & Tomomi Kinoshita & Sakiko Ishihara & Shu-ichi Ikeda - 1231-1240 Safety Profile of Eslicarbazepine Acetate as Add-On Therapy in Adults with Refractory Focal-Onset Seizures: From Clinical Studies to 6 Years of Post-Marketing Experience
by Helena Gama & Mariana Vieira & Raquel Costa & Joana Graça & Luís M. Magalhães & Patrício Soares-da-Silva - 1241-1248 Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance
by Victoria Newbould & Steven Meur & Thomas Goedecke & Xavier Kurz - 1249-1258 Drug-Induced Dental Caries: A Disproportionality Analysis Using Data from VigiBase
by Emilie Patras Campaigno & Inès Kebir & Jean-Louis Montastruc & Manuela Rueter & Delphine Maret & Maryse Lapeyre-Mestre & Brigitte Sallerin & Fabien Despas - 1259-1277 A Pharmacoepidemiology Database System for Monitoring Risk Due to the Use of Medicines by New Zealand Primary Care Patients
by Andrew M. Tomlin & David M. Reith & David J. Woods & Hywel S. Lloyd & Alesha Smith & John S. Fountain & Murray W. Tilyard - 1279-1292 Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications
by Rachel B. Weinstein & Patrick Ryan & Jesse A. Berlin & Amy Matcho & Martijn Schuemie & Joel Swerdel & Kayur Patel & Daniel Fife - 1293-1293 Correction to: Medication Errors: A Characterisation of Spontaneously Reported Cases in EudraVigilance
by Victoria Newbould & Steven Meur & Thomas Goedecke & Xavier Kurz - 1295-1295 Correction to: Safety Concerns with HPV Vaccines Continue to Linger: Are Current Vaccine Pharmacovigilance Practices Sufficient?
by Rebecca E. Chandler
November 2017, Volume 40, Issue 11
- 1047-1048 Pharmacovigilance Using Textual Data: The Need to Go Deeper and Wider into the Con(text)
by Tavpritesh Sethi & Nigam H. Shah - 1049-1074 Clinical Relevance and Predictive Value of Damage Biomarkers of Drug-Induced Kidney Injury
by Sandra L. Kane-Gill & Pamela L. Smithburger & Kianoush Kashani & John A. Kellum & Erin Frazee - 1075-1089 Natural Language Processing for EHR-Based Pharmacovigilance: A Structured Review
by Yuan Luo & William K. Thompson & Timothy M. Herr & Zexian Zeng & Mark A. Berendsen & Siddhartha R. Jonnalagadda & Matthew B. Carson & Justin Starren - 1091-1098 Safety and Interactions of Direct Oral Anticoagulants with Antiarrhythmic Drugs
by Ipek Celikyurt & Christoph R. Meier & Michael Kühne & Beat Schaer - 1099-1107 Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database
by Cécile Pageot & Julien Bezin & Andy Smith & Mickael Arnaud & Francesco Salvo & Françoise Haramburu & Bernard Bégaud & Antoine Pariente - 1109-1118 Association of Parkinsonism or Parkinson Disease with Polypharmacy in the Year Preceding Diagnosis: A Nested Case–Control Study in South Korea
by Hae-Young Park & Ji-Won Park & Hyun Soon Sohn & Jin-Won Kwon - 1119-1129 Using Multiple Pharmacovigilance Models Improves the Timeliness of Signal Detection in Simulated Prospective Surveillance
by Rolina D. van Gaalen & Michal Abrahamowicz & David L. Buckeridge - 1131-1140 Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System
by Paola Maria Cutroneo & Claudia Giardina & Valentina Ientile & Simona Potenza & Laura Sottosanti & Carmen Ferrajolo & Costantino J. Trombetta & Gianluca Trifirò - 1141-1146 Signal of Miscarriage with Aripiprazole: A Disproportionality Analysis of the Japanese Adverse Drug Event Report Database
by Takamasa Sakai & Fumiko Ohtsu & Chiyo Mori & Kouichi Tanabe & Nobuyuki Goto - 1147-1155 The Fetal Safety of Enoxaparin Use During Pregnancy: A Population-Based Retrospective Cohort Study
by Meital Shlomo & Rafael Gorodischer & Sharon Daniel & Arnon Wiznitzer & Ilan Matok & Boris Fishman & Gideon Koren & Amalia Levy
October 2017, Volume 40, Issue 10
- 841-844 The New Phase of ISoP
by Sten Olsson & Ian C. K. Wong & Jean-Christophe Delumeau & Mira Harrison-Woolrych - 845-849 A New Erice Report Considering the Safety of Medicines in the 21st Century
by Ivor Ralph Edwards - 851-853 Statin Therapy and Risk of Intracranial Hemorrhage in Patients with Ischemic Stroke
by Matilda Florentin & Moses S. Elisaf - 855-869 Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works
by Aniello Santoro & Georgy Genov & Almath Spooner & June Raine & Peter Arlett - 871-886 Frequency and Nature of Medication Errors and Adverse Drug Events in Mental Health Hospitals: a Systematic Review
by Ghadah H. Alshehri & Richard N. Keers & Darren M. Ashcroft - 887-893 Lipophilic Statins and the Risk of Intracranial Hemorrhage Following Ischemic Stroke: A Population-Based Study
by Kieran L. Quinn & Erin M. Macdonald & Muhammad M. Mamdani & Christina Diong & David N. Juurlink - 895-909 Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database
by Alice Capogrosso Sansone & Irma Convertino & Maria Teresa Galiulo & Stefano Salvadori & Stefania Pieroni & Tamara Knezevic & Stefania Mantarro & Alessandra Marino & Manfred Hauben & Corrado Blandizzi & Marco Tuccori - 911-921 Patients’ Perspectives on Adverse Drug Reaction Reporting in a Developing Country: A Case Study from Ghana
by George Tsey Sabblah & Delese Mimi Darko & Hudu Mogtari & Linda Härmark & Eugène Puijenbroek - 923-932 Updating the Evidence of the Interaction Between Clopidogrel and CYP2C19-Inhibiting Selective Serotonin Reuptake Inhibitors: A Cohort Study and Meta-Analysis
by Katsiaryna Bykov & Sebastian Schneeweiss & Robert J. Glynn & Murray A. Mittleman & David W. Bates & Joshua J. Gagne - 933-934 Brian A. Baldo, Safety of Biologics Therapy: Monoclonal Antibodies, Cytokines, Fusion Proteins, Hormones, Enzymes, Coagulation Proteins, Vaccines, Botulinum Toxins, 1st Edition, Springer, 2016, Print Book ISBN: 978-3-319-30470-0, e-Book ISBN 978-3-319-30472-4
by Kevin Broady - 935-936 Comment on “Patient Reporting in the EU: Analysis of EudraVigilance Data”
by Farid Kheloufi & Anne Default & Frank Rouby & Olivier Blin & Joelle Micallef
September 2017, Volume 40, Issue 9
- 757-760 Using Simulated Data to Assess Case-Crossover Designs for Studying Less Transient Effects of Drugs
by Malcolm Maclure - 761-769 Potential Teratogenic Effects of Clomiphene Citrate
by Alessandra Scaparrotta & Francesco Chiarelli & Alberto Verrotti - 771-781 Second-Generation Antipsychotics and Metabolic Side Effects: A Systematic Review of Population-Based Studies
by Lauren Hirsch & Jaeun Yang & Lauren Bresee & Nathalie Jette & Scott Patten & Tamara Pringsheim - 783-787 The Incidence of Drug- and Herbal and Dietary Supplement-Induced Liver Injury: Preliminary Findings from Gastroenterologist-Based Surveillance in the Population of the State of Delaware
by Maricruz Vega & Manisha Verma & David Beswick & Stephanie Bey & Jared Hossack & Nathan Merriman & Ashish Shah & Victor Navarro - 789-798 Evaluation of the Case–Crossover (CCO) Study Design for Adverse Drug Event Detection
by Zachary Burningham & Tao He & Chia-Chen Teng & Xi Zhou & Jonathan Nebeker & Brian C. Sauer - 799-808 An Algorithm to Identify Generic Drugs in the FDA Adverse Event Reporting System
by Geetha Iyer & Sathiya Priya Marimuthu & Jodi B. Segal & Sonal Singh - 809-821 Role of Medicines of Unknown Identity in Adverse Drug Reaction-Related Hospitalizations in Developing Countries: Evidence from a Cross-Sectional Study in a Teaching Hospital in the Lao People’s Democratic Republic
by Céline Caillet & Chanvilay Sichanh & Gaëtan Assemat & Myriam Malet-Martino & Agnès Sommet & Haleh Bagheri & Noudy Sengxeu & Niphonh Mongkhonmath & Mayfong Mayxay & Lamphone Syhakhang & Maryse Lapeyre-Mestre & Paul N. Newton & Anne Roussin - 823-834 Occurrence of Multiple Sclerosis After Drug Exposure: Insights From Evidence Mapping
by Ippazio Cosimo Antonazzo & Emanuel Raschi & Luca Vignatelli & Elisa Baldin & Trond Riise & Roberto D’Alessandro & Fabrizio De Ponti & Elisabetta Poluzzi - 835-840 Macrolides, Digoxin Toxicity and the Risk of Sudden Death: A Population-Based Study
by Kieran L. Quinn & Erin M. Macdonald & Tara Gomes & Muhammad M. Mamdani & Anjie Huang & David N. Juurlink
August 2017, Volume 40, Issue 8
- 647-649 Good Intentions, But What About Unintended Consequences?
by Helen C. Kales & Donovan T. Maust - 651-661 Species Adulteration in the Herbal Trade: Causes, Consequences and Mitigation
by Ramanujam Srirama & J. U. Santhosh Kumar & G. S. Seethapathy & Steven G. Newmaster & S. Ragupathy & K. N. Ganeshaiah & R. Uma Shaanker & Gudasalamani Ravikanth - 663-677 Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis
by Angel Y. S. Wong & Esther W. Chan & Shweta Anand & Alan J. Worsley & Ian C. K. Wong - 679-692 Antipsychotic Prescribing to Patients Diagnosed with Dementia Without a Diagnosis of Psychosis in the Context of National Guidance and Drug Safety Warnings: Longitudinal Study in UK General Practice
by S. Jill Stocks & Evangelos Kontopantelis & Roger T. Webb & Anthony J. Avery & Alistair Burns & Darren M. Ashcroft - 693-702 Adjuvanted (AS03) A/H1N1 2009 Pandemic Influenza Vaccines and Solid Organ Transplant Rejection: Systematic Signal Evaluation and Lessons Learnt
by Gaël Dos Santos & Harry A. Seifert & Vincent Bauchau & Vivek Shinde & Dominique M. Barbeau & Catherine Cohet - 703-713 Detecting Signals of Disproportionate Reporting from Singapore’s Spontaneous Adverse Event Reporting System: An Application of the Sequential Probability Ratio Test
by Cheng Leng Chan & Sowmya Rudrappa & Pei San Ang & Shu Chuen Li & Stephen J. W. Evans - 715-727 Preliminary Results of a Novel Algorithmic Method Aiming to Support Initial Causality Assessment of Routine Pharmacovigilance Case Reports for Medication-Induced Liver Injury: The PV-RUCAM
by Erik Scalfaro & Henk Johan Streefkerk & Michael Merz & Christoph Meier & David Lewis - 729-742 Communication on Safety of Medicines in Europe: Current Practices and General Practitioners’ Awareness and Preferences
by Sieta T. Vries & Maartje J. M. Sar & Amelia Cupelli & Ilaria Baldelli & Anna Marie Coleman & Dolores Montero & Ivana Šipić & Adriana Andrić & Annika Wennberg & Jane Ahlqvist-Rastad & Petra Denig & Peter G. M. Mol - 743-754 People’s Understanding of Verbal Risk Descriptors in Patient Information Leaflets: A Cross-Sectional National Survey of 18- to 65-Year-Olds in England
by Rebecca K. Webster & John Weinman & G James Rubin - 755-755 Comment on: “Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts”
by Viroj Wiwanitkit
July 2017, Volume 40, Issue 7
- 543-546 The Power of the Case Narrative - Can it be Brought to Bear on Duplicate Detection?
by G. Niklas Norén - 547-558 Summarising the Evidence for Drug Safety: A Methodological Discussion of Different Meta-Analysis Approaches
by Guillermo Prada-Ramallal & Bahi Takkouche & Adolfo Figueiras - 559-570 Targeting Interleukin-5 or Interleukin-5Rα: Safety Considerations
by Diego Bagnasco & Matteo Ferrando & Marco Caminati & Alice Bragantini & Francesca Puggioni & Gilda Varricchi & Giovanni Passalacqua & Giorgio Walter Canonica - 571-582 Using Probabilistic Record Linkage of Structured and Unstructured Data to Identify Duplicate Cases in Spontaneous Adverse Event Reporting Systems
by Kory Kreimeyer & David Menschik & Scott Winiecki & Wendy Paul & Faith Barash & Emily Jane Woo & Meghna Alimchandani & Deepa Arya & Craig Zinderman & Richard Forshee & Taxiarchis Botsis - 583-596 Drospirenone-Containing Oral Contraceptive Pills and the Risk of Venous Thromboembolism: An Assessment of Risk in First-Time Users and Restarters
by Natasha Larivée & Samy Suissa & Janie Coulombe & Vicky Tagalakis & Kristian B. Filion - 597-606 Adverse Drug Reaction-Related Hospitalizations in Elderly Australians: A Prospective Cross-Sectional Study in Two Tasmanian Hospitals
by Nibu Parameswaran Nair & Leanne Chalmers & Bonnie J. Bereznicki & Colin Curtain & Gregory M. Peterson & Michael Connolly & Luke R. Bereznicki - 607-614 The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis
by Leàn Rolfes & Florence Hunsel & Laura Linden & Katja Taxis & Eugène Puijenbroek - 615-627 Impact of Safety-Related Regulations on Codeine Use in Children: A Quasi-Experimental Study Using Taiwan’s National Health Insurance Research Database
by Chih-Wan Lin & Ching-Huan Wang & Wei-I Huang & Wei-Ming Ke & Pi-Hui Chao & Wen-Wen Chen & Fei-Yuan Hsiao - 629-645 Patient Reporting in the EU: Analysis of EudraVigilance Data
by Marin Banovac & Gianmario Candore & Jim Slattery & Francois Houÿez & David Haerry & Georgy Genov & Peter Arlett
June 2017, Volume 40, Issue 6
- 457-459 Medicines Save, Medicines Kill
by Joel Lexchin - 461-464 Drug-Induced Arrhythmia: Bridging the Gap Between Pathophysiological Knowledge and Clinical Practice
by Elisabetta Poluzzi & Emanuel Raschi & Igor Diemberger & Fabrizio De Ponti - 465-474 Adverse Drug Event Causality Analysis (ADECA): A Process for Evaluating Evidence and Assigning Drugs to Risk Categories for Sudden Death
by Raymond L. Woosley & Klaus Romero & Craig W. Heise & Tyler Gallo & Jared Tate & Raymond David Woosley & Sophie Ward - 475-482 Pharmacovigilance of Regenerative Medicine Under the Amended Pharmaceutical Affairs Act in Japan
by Yasuko Inokuma - 483-495 Evaluation of ‘SAEFVIC’, A Pharmacovigilance Surveillance Scheme for the Spontaneous Reporting of Adverse Events Following Immunisation in Victoria, Australia
by Hazel J. Clothier & Nigel W. Crawford & Melissa Russell & Heath Kelly & Jim P. Buttery - 497-503 Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals
by Andreas Schick & Kathleen L. Miller & Michael Lanthier & Gerald Dal Pan & Clark Nardinelli - 505-515 The Risk of Ischemic Cardio- and Cerebrovascular Events Associated with Oxycodone–Naloxone and Other Extended-Release High-Potency Opioids: A Nested Case–Control Study
by Kathrin Jobski & Bianca Kollhorst & Edeltraut Garbe & Tania Schink - 517-530 A Survey on Pharmacovigilance Activities in ASEAN and Selected Non-ASEAN Countries, and the Use of Quantitative Signal Detection Algorithms
by Cheng Leng Chan & Pei San Ang & Shu Chuen Li - 531-542 Patient and Physician Perceptions of Drug Safety Information for Sleep Aids: A Qualitative Study
by Aaron S. Kesselheim & Sarah A. McGraw & Sara Z. Dejene & Paula Rausch & Gerald J. Dal Pan & Brian M. Lappin & Esther H. Zhou & Jerry Avorn & Eric G. Campbell
May 2017, Volume 40, Issue 5
- 363-364 Antenatal Exposure and Diseases in the Offspring: The Role of Big Data
by Christoph R. Meier & Susan S. Jick - 365-372 Causality Assessment in Pharmacovigilance: Still a Challenge
by I. Ralph Edwards - 373-386 Anti-Angiogenic Tyrosine Kinase Inhibitors and Reversible Posterior Leukoencephalopathy Syndrome: Could Hypomagnesaemia Be the Trigger?
by Rashmi R. Shah - 387-397 Sensitivity of the UK Clinical Practice Research Datalink to Detect Neurodevelopmental Effects of Medicine Exposure in Utero: Comparative Analysis of an Antiepileptic Drug-Exposed Cohort
by R. A. Charlton & A. McGrogan & J. Snowball & L. M. Yates & A. Wood & J. Clayton-Smith & W. H. Smithson & J. L. Richardson & N. McHugh & S. H. L. Thomas & G. A. Baker & R. Bromley - 399-408 Validation of New Signal Detection Methods for Web Query Log Data Compared to Signal Detection Algorithms Used With FAERS
by Susan Colilla & Elad Yom Tov & Ling Zhang & Marie-Laure Kurzinger & Stephanie Tcherny-Lessenot & Catherine Penfornis & Shang Jen & Danny S. Gonzalez & Patrick Caubel & Susan Welsh & Juhaeri Juhaeri - 409-418 Feasibility and Educational Value of a Student-Run Pharmacovigilance Programme: A Prospective Cohort Study
by Tim Schutte & Jelle Tichelaar & Michael O. Reumerman & Rike Eekeren & Leàn Rolfes & Eugène P. Puijenbroek & Milan C. Richir & Michiel A. Agtmael - 419-430 Evaluation of Potentially Drug-Related Patient-Reported Common Symptoms Assessed During Clinical Medication Reviews: A Cross-Sectional Observational Study
by Tim W. A. Schoenmakers & Martina Teichert & Michel Wensing & Peter A. G. M. Smet - 431-441 Post-Marketing Regulation of Medicines Withdrawn from the Market Because of Drug-Attributed Deaths: An Analysis of Justification
by Igho J. Onakpoya & Carl J. Heneghan & Jeffrey K. Aronson - 443-455 Factors Influencing the Use of a Mobile App for Reporting Adverse Drug Reactions and Receiving Safety Information: A Qualitative Study
by Sieta T. Vries & Lisa Wong & Alastair Sutcliffe & François Houÿez & Carmen Lasheras Ruiz & Peter G. M. Mol
April 2017, Volume 40, Issue 4
- 273-283 Pre-Exposure Prophylaxis for HIV Prevention: Safety Concerns
by Raymond A. Tetteh & Barbara A. Yankey & Edmund T. Nartey & Margaret Lartey & Hubert G. M. Leufkens & Alexander N. O. Dodoo - 285-292 Digitalis Use and the Risk of Breast Cancer: A Systematic Review and Meta-Analysis
by Chen Zhang & Shao-Hua Xie & Bingfei Xu & Shi Lu & Pian Liu - 293-303 Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports
by Zahra Anita Trippe & Bruno Brendani & Christoph Meier & David Lewis - 305-315 Antibiotic-Induced Liver Injury in Paediatric Outpatients: A Case-Control Study in Primary Care Databases
by Carmen Ferrajolo & Katia M. C. Verhamme & Gianluca Trifirò & Geert W. ‘t Jong & Gino Picelli & Carlo Giaquinto & Giampiero Mazzaglia & Bruno H. Stricker & Francesco Rossi & Annalisa Capuano & Miriam C. J. M. Sturkenboom - 317-331 Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts
by Carrie E. Pierce & Khaled Bouri & Carol Pamer & Scott Proestel & Harold W. Rodriguez & Hoa Le & Clark C. Freifeld & John S. Brownstein & Mark Walderhaug & I. Ralph Edwards & Nabarun Dasgupta - 333-341 Effectiveness of Risk Evaluation and Mitigation Strategies (REMS) for Lenalidomide and Thalidomide: Patient Comprehension and Knowledge Retention
by Nancy A. Brandenburg & Robert Bwire & John Freeman & Florence Houn & Paul Sheehan & Jerome B. Zeldis - 343-350 Signal Detection Based on Time to Onset Algorithm in Spontaneous Reporting System of China
by Tianyi Zhang & Xiaofei Ye & Xiaojing Guo & Guizhi Wu & Yongfang Hou & Jinfang Xu & Wentao Shi & Tiantian Zhu & Yuan Zhang & Xinji Zhang & Jiaqi Song & Jia He - 351-358 Diverging Conclusions from the Same Meta-Analysis in Drug Safety: Source of Data (Primary Versus Secondary) Takes a Toll
by Guillermo Prada-Ramallal & Bahi Takkouche & Adolfo Figueiras - 359-360 Comment on: “Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France”
by Alain Braillon - 361-362 Authors’ Reply to Alain Braillon’s Comment on “Proactive regional pharmacovigilance system versus national spontaneous reporting for collecting safety data on concerning off-label prescribing practices: An example with baclofen and alcohol dependence in France’’
by Marine Auffret & Julien Labreuche & Alain Duhamel & Sylvie Deheul & Olivier Cottencin & Régis Bordet & Sophie Gautier & Benjamin Rolland
March 2017, Volume 40, Issue 3
- 191-199 Developing a Crowdsourcing Approach and Tool for Pharmacovigilance Education Material Delivery
by Andrew Bate & Jürgen Beckmann & Alexander Dodoo & Linda Härmark & Kenneth Hartigan-Go & Anna Hegerius & Marie Lindquist & Eugène Puijenbroek & Marco Tuccori & Ulrich Hagemann - 201-210 Benefits and Risks of Long-Term Asthma Management in Children: Where Are We Heading?
by Hengameh H. Raissy & H. William Kelly - 211-228 Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity?
by Rashmi R. Shah - 229-240 Cancer Event Rate and Mortality with Thienopyridines: A Systematic Review and Meta-Analysis
by Rafail Angelos Kotronias & Chun Shing Kwok & Chun Wai Wong & Tim Kinnaird & Azfar Zaman & Mamas A. Mamas - 241-248 Effect of Medications for Gastric Acid-Related Symptoms on Total Motile Sperm Count and Concentration: A Case–Control Study in Men of Subfertile Couples from the Netherlands
by Nicole A. Huijgen & Hedwig J. Goijen & John M. Twigt & Annemarie G. M. G. J. Mulders & Jan Lindemans & Gert R. Dohle & Joop S. E. Laven & Régine P. M. Steegers-Theunissen - 249-255 Melanoma and Non-Melanoma Skin Cancer Associated with Angiotensin-Converting-Enzyme Inhibitors, Angiotensin-Receptor Blockers and Thiazides: A Matched Cohort Study
by Beatrice Nardone & Sara Majewski & Ashley S. Kim & Tina Kiguradze & Estela M. Martinez-Escala & Rivka Friedland & Ahmad Amin & Anne E. Laumann & Beatrice J. Edwards & Alfred W. Rademaker & Mary C. Martini & Dennis P. West - 257-262 Proactive Regional Pharmacovigilance System Versus National Spontaneous Reporting for Collecting Safety Data on Concerning Off-Label Prescribing Practices: An Example with Baclofen and Alcohol Dependence in France
by Marine Auffret & Julien Labreuche & Alain Duhamel & Sylvie Deheul & Olivier Cottencin & Régis Bordet & Sophie Gautier & Benjamin Rolland - 263-272 The Impact of Provider Networks on the Co-Prescriptions of Interacting Drugs: A Claims-Based Analysis
by Mei-Sing Ong & Karen L. Olson & Laura Chadwick & Chunfu Liu & Kenneth D. Mandl
February 2017, Volume 40, Issue 2
- 101-103 Generating Evidence of Clinical Outcomes of Drug–Drug Interactions
by Katsiaryna Bykov & Joshua J. Gagne - 105-108 Active Surveillance of Follow-on Biologics: A Prescription for Uptake
by Ameet Sarpatwari & Joshua J. Gagne & Nicole L. Levidow & Aaron S. Kesselheim - 109-113 Should Domperidone be Used as a Galactagogue? Possible Safety Implications for Mother and Child
by Luc M. Hondeghem & Noël H. Logghe - 115-119 Bone Fractures with Sodium-Glucose Co-transporter-2 Inhibitors: How Real is the Risk?
by Edoardo Mannucci & Matteo Monami - 121-132 The Risk of Adverse Pregnancy Outcome After First Trimester Exposure to H1 Antihistamines: A Systematic Review and Meta-Analysis
by Fatma Etwel & Lauren H. Faught & Michael J. Rieder & Gideon Koren - 133-144 Investigating the Additive Interaction of QT-Prolonging Drugs in Older People Using Claims Data
by Andreas D. Meid & Anna Medem & Dirk Heider & Jürgen-Bernhard Adler & Christian Günster & Hanna M. Seidling & Renate Quinzler & Hans-Helmut König & Walter E. Haefeli - 145-152 Surveillance of Adverse Events After Seasonal Influenza Vaccination in Pregnant Women and Their Infants in the Vaccine Adverse Event Reporting System, July 2010–May 2016
by Pedro Moro & Jane Baumblatt & Paige Lewis & Janet Cragan & Naomi Tepper & Maria Cano - 153-167 Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study
by Marten A. Lantinga & Hedwig M. A. D’Agnolo & Niek F. Casteleijn & Johan W. Fijter & Esther Meijer & Annemarie L. Messchendorp & Dorien J. M. Peters & Mahdi Salih & Edwin M. Spithoven & Darius Soonawala & Folkert W. Visser & Jack F. M. Wetzels & Robert Zietse & Joost P. H. Drenth & Ron T. Gansevoort - 169-181 Propensity Score Weighting Compared to Matching in a Study of Dabigatran and Warfarin
by John D. Seeger & Katsiaryna Bykov & Dorothee B. Bartels & Krista Huybrechts & Sebastian Schneeweiss - 183-185 Comment on: "Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter"
by Emilie Jouanjus & Michel Mallaret & Joëlle Micallef & Camille Ponté & Anne Roussin & Maryse Lapeyre-Mestre - 187-188 Authors’ Reply to Jouanjus and Colleagues’ Comment on “Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter”
by Abeed Sarker & Dan Malone & Graciela Gonzalez - 189-189 Erratum to: Association Between Statin Use and Bell’s Palsy: A Population-Based Study
by Shih-Han Hung & Li-Hsuan Wang & Herng-Ching Lin & Shiu-Dong Chung
January 2017, Volume 40, Issue 1
- 1-2 On the Potential of Preemptive Genotyping Towards Preventing Medication-Related Adverse Events: Results from the South Korean National Health Insurance Database
by Jonathan S. Schildcrout & Joshua C. Denny & Dan M. Roden - 3-14 The Harms of Antipsychotic Drugs: Evidence from Key Studies
by Thomas J. Moore & Curt D. Furberg - 15-36 Pharmaceutical Benefit–Risk Communication Tools: A Review of the Literature
by Dominic Way & Hortense Blazsin & Ragnar Löfstedt & Frederic Bouder - 37-47 Evaluating the Safety Profile of Non-Active Implantable Medical Devices Compared with Medicines
by Josep Pane & Preciosa M. Coloma & Katia M. C. Verhamme & Miriam C. J. M. Sturkenboom & Irene Rebollo - 49-59 Vancomycin-Induced Thrombocytopenia: A Narrative Review
by Mehdi Mohammadi & Zahra Jahangard-Rafsanjani & Amir Sarayani & Molouk Hadjibabaei & Maryam Taghizadeh-Ghehi - 61-64 Proton Pump Inhibitors and Risk of Rhabdomyolysis
by Scott J. Duncan & Colin W. Howden - 65-80 Role of Preemptive Genotyping in Preventing Serious Adverse Drug Events in South Korean Patients
by Grace Juyun Kim & Soo Youn Lee & Ji Hye Park & Brian Y. Ryu & Ju Han Kim - 81-90 Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase®
by Rebecca E. Chandler & Kristina Juhlin & Jonas Fransson & Ola Caster & I. Ralph Edwards & G. Niklas Norén - 91-100 The Role of Hemoglobin Laboratory Test Results for the Detection of Upper Gastrointestinal Bleeding Outcomes Resulting from the Use of Medications in Observational Studies
by Elisabetta Patorno & Joshua J. Gagne & Christine Y. Lu & Kevin Haynes & Andrew T. Sterrett & Jason Roy & Xingmei Wang & Marsha A. Raebel
December 2016, Volume 39, Issue 12
- 1161-1162 On Designs for Vaccine Surveillance
by Robert W. Platt - 1163-1174 Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs
by Emanuele D’Amico & Aurora Zanghì & Carmela Leone & Hayrettin Tumani & Francesco Patti - 1175-1187 Risk–Benefit Profile of Direct-Acting Oral Anticoagulants in Established Therapeutic Indications: An Overview of Systematic Reviews and Observational Studies
by Emanuel Raschi & Matteo Bianchin & Walter Ageno & Roberto De Ponti & Fabrizio De Ponti - 1189-1195 Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre: A Descriptive Study
by Geneviève Durrieu & Julien Jacquot & Mathilde Mège & Emmanuelle Bondon-Guitton & Vanessa Rousseau & François Montastruc & Jean-Louis Montastruc - 1197-1209 Vaccine Case–Population: A New Method for Vaccine Safety Surveillance
by Hélène Théophile & Nicholas Moore & Philip Robinson & Bernard Bégaud & Antoine Pariente - 1211-1227 Estimating Herbal Product Authentication and Adulteration in India Using a Vouchered, DNA-Based Biological Reference Material Library
by Dhivya Shanmughanandhan & Subramanyam Ragupathy & Steven G. Newmaster & Saravanan Mohanasundaram & Ramalingam Sathishkumar - 1229-1237 The Risk of Achilles or Biceps Tendon Rupture in New Statin Users: A Propensity Score-Matched Sequential Cohort Study
by Julia Spoendlin & J. Bradley Layton & Mallika Mundkur & Christian Meier & Susan S. Jick & Christoph R. Meier - 1239-1250 Knowledge of Adverse Drug Reaction Reporting Among Healthcare Professionals in Bhutan: A Cross-Sectional Survey
by Choki Dorji & Pramote Tragulpiankit & Arthorn Riewpaiboon & Tashi Tobgay
November 2016, Volume 39, Issue 11
- 1043-1051 National ADR Monitoring System in China
by Yongfang Hou & Xinling Li & Guizhi Wu & Xiaofei Ye - 1053-1072 Drug–Drug Interactions, Effectiveness, and Safety of Hormonal Contraceptives in Women Living with HIV
by Kimberly K. Scarsi & Kristin M. Darin & Catherine A. Chappell & Stephanie M. Nitz & Mohammed Lamorde - 1073-1091 Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas
by Rashmi R. Shah - 1093-1104 Pattern of Onset and Risk Factors for Peripheral Oedema During Vildagliptin Use: Analysis from the Vildagliptin Prescription–Event Monitoring Study in England
by Deborah Layton & Abigail L. Coughtrie & Naseer Qayum & Saad A. W. Shakir - 1105-1116 Patient Reporting of Adverse Drug Reactions: An International Survey of National Competent Authorities’ Views and Needs
by Cristiano Matos & Linda Härmark & Florence Hunsel - 1117-1127 A Survey of Adverse Event Reporting Practices Among US Healthcare Professionals
by Stella Stergiopoulos & Carrie A. Brown & Thomas Felix & Gustavo Grampp & Kenneth A. Getz - 1129-1137 Prevention of Medication Errors in Hospitalized Patients: The Japan Adverse Drug Events Study
by Chihiro Noguchi & Mio Sakuma & Yoshinori Ohta & David W. Bates & Takeshi Morimoto - 1139-1149 Association Between the Occurrence of Adverse Drug Events and Modification of First-Line Highly Active Antiretroviral Therapy in Ghanaian HIV Patients
by Raymond A. Tetteh & Edmund T. Nartey & Margaret Lartey & Aukje K. Mantel-Teeuwisse & Hubert G. M. Leufkens & Barbara A. Yankey & Alexander N. O. Dodoo - 1151-1152 Comment on: “Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence”
by Alain Braillon - 1153-1154 Authors’ Reply to Alain Braillon’s Comment on “Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence”
by Julia M. A. Sinclair & Sophia E. Chambers & David S. Baldwin
October 2016, Volume 39, Issue 10
- 883-890 Patient-Reported Safety Information: A Renaissance of Pharmacovigilance?
by Linda Härmark & June Raine & Hubert Leufkens & I. Ralph Edwards & Ugo Moretti & Viola Macolic Sarinic & Agnes Kant - 891-894 Pacific Island Pharmacovigilance: The Need for a Different Approach
by John McEwen & Lasse S. Vestergaard & Amanda L. C. Sanburg - 895-901 Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns
by Stephen A. Goldman - 903-924 Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects
by Irma Convertino & Alice Capogrosso Sansone & Alessandra Marino & Maria T. Galiulo & Stefania Mantarro & Luca Antonioli & Matteo Fornai & Corrado Blandizzi & Marco Tuccori - 925-943 Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions
by Mahmoud Slim & Inmaculada Medina-Caliz & Andres Gonzalez-Jimenez & M. Rosario Cabello & Fermin Mayoral-Cleries & M. Isabel Lucena & Raul J. Andrade - 945-957 Neuropsychiatric Effects of HIV Antiviral Medications
by Glenn J. Treisman & Olivia Soudry - 959-976 Targeted Spontaneous Reporting: Assessing Opportunities to Conduct Routine Pharmacovigilance for Antiretroviral Treatment on an International Scale
by Beth Rachlis & Rakhi Karwa & Celia Chema & Sonak Pastakia & Sten Olsson & Kara Wools-Kaloustian & Beatrice Jakait & Mercy Maina & Marcel Yotebieng & Nagalingeswaran Kumarasamy & Aimee Freeman & Nathalie de Rekeneire & Stephany N. Duda & Mary-Ann Davies & Paula Braitstein - 977-988 Innovative Digital Tools and Surveillance Systems for the Timely Detection of Adverse Events at the Point of Care: A Proof-of-Concept Study
by Christian Hoppe & Patrick Obermeier & Susann Muehlhans & Maren Alchikh & Lea Seeber & Franziska Tief & Katharina Karsch & Xi Chen & Sindy Boettcher & Sabine Diedrich & Tim Conrad & Bron Kisler & Barbara Rath
September 2016, Volume 39, Issue 9
- 779-785 The Patient’s Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization
by Meredith Y. Smith & Isma Benattia - 787-799 Benefit–Risk Assessment of Fish Oil in Preventing Cardiovascular Disease
by Bill Lands - 801-821 Drug-Induced Liver Injury: Highlights from a Review of the 2015 Literature
by Philip Sarges & Joshua M Steinberg & James H Lewis - 823-840 Benefit and Risk of Tofacitinib in the Treatment of Rheumatoid Arthritis: A Focus on Herpes Zoster
by Kunihiro Yamaoka - 841-845 Drug Interactions of Direct-Acting Oral Anticoagulants
by John Leonard Fitzgerald & Laurence Guy Howes - 847-857 Adverse-Drug-Reaction-Related Hospitalisations in Developed and Developing Countries: A Review of Prevalence and Contributing Factors
by Mulugeta Tarekegn Angamo & Leanne Chalmers & Colin M. Curtain & Luke R. E. Bereznicki - 859-872 Active Surveillance versus Spontaneous Reporting for First-Line Antiretroviral Medicines in Namibia: A Cost–Utility Analysis
by Marita Mann & Assegid Mengistu & Johannes Gaeseb & Evans Sagwa & Greatjoy Mazibuko & Joseph B. Babigumira & Louis P. Garrison & Andy Stergachis - 873-881 Drug Safety Monitoring in Children: Performance of Signal Detection Algorithms and Impact of Age Stratification
by Osemeke U. Osokogu & Caitlin Dodd & Alexandra Pacurariu & Florentia Kaguelidou & Daniel Weibel & Miriam C. J. M. Sturkenboom
August 2016, Volume 39, Issue 8
- 715-727 Contemporary Reflections on the Safety of Long-Term Aspirin Treatment for the Secondary Prevention of Cardiovascular Disease
by Alexander C. Fanaroff & Matthew T. Roe - 729-744 Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease
by Rolf Teschke & Gaby Danan - 745-748 Age at First Rotavirus Vaccination and Risk of Intussusception in Infants: A Public Health Modeling Analysis
by Chee Fu Yung & Chia Yin Chong & Koh Cheng Thoon - 749-754 Risk of Liver Injury Associated with Green Tea Extract in SLIMQUICK® Weight Loss Products: Results from the DILIN Prospective Study
by Elizabeth X. Zheng & Simona Rossi & Robert J. Fontana & Raj Vuppalanchi & Jay H. Hoofnagle & Ikhlas Khan & Victor J. Navarro - 755-762 Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis
by Megan E. B. Clowse & Steven R. Feldman & John D. Isaacs & Alexandra B. Kimball & Vibeke Strand & Richard B. Warren & Daniel Xibillé & Yan Chen & Donald Frazier & Jamie Geier & James Proulx & Amy Marren - 763-768 Artesunate/Amodiaquine-Induced Acute Extrapyramidal Reactions in Children and Younger Adults: Case Series Assessment
by Mulugeta Russom & Dawit Tesfai & Semere Gebregiorgis & Abdulmumini Usman & Selam Mihreteab & Iyassu Bahta & Elsa Mekonnen & Selamawit Ghebrehiwet & Gelila Abrham - 769-776 The Impact of Experiencing Adverse Drug Reactions on the Patient’s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands
by Leàn Rolfes & Florence Hunsel & Katja Taxis & Eugène Puijenbroek - 777-778 Is Earlier Signal Detection Always Better?
by Alan M. Hochberg & Stella Stergiopoulos
July 2016, Volume 39, Issue 7
- 589-611 Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and/or Renal Impairment
by Elise J. Smolders & Clara T. M. M. Kanter & Bart Hoek & Joop E. Arends & Joost P. H. Drenth & David M. Burger - 613-626 Neurocognitive Adverse Effects of Anesthesia in Adults and Children: Gaps in Knowledge
by Christopher G. Ward & Roderic G. Eckenhoff - 627-645 Safety and Tolerability of Pharmacological Treatment of Alcohol Dependence: Comprehensive Review of Evidence
by Julia M. A. Sinclair & Sophia E. Chambers & Celia J. Shiles & David S. Baldwin
June 2016, Volume 39, Issue 6
- 491-500 Medication Errors: New EU Good Practice Guide on Risk Minimisation and Error Prevention
by Thomas Goedecke & Kathryn Ord & Victoria Newbould & Sabine Brosch & Peter Arlett - 501-508 Safety Considerations with Dual Bronchodilator Therapy in COPD: An Update
by Maria Gabriella Matera & Paola Rogliani & Luigino Calzetta & Mario Cazzola - 509-516 The Safety of Prochlorperazine in Children: A Systematic Review and Meta-Analysis
by Melissa Lau Moon Lin & Paula D. Robinson & Jacqueline Flank & Lillian Sung & L. Lee Dupuis
May 2016, Volume 39, Issue 5
- 371-373 Measuring Signal Detection Performance: Can We Trust Negative Controls and Do We Need Them?
by Jim Slattery - 375-380 Maximizing the Post-Approval Safety of Flibanserin: A Role for Regulators, Clinicians, and Patients
by Sheriza N. Baksh & Walid F. Gellad & G. Caleb Alexander - 381-399 Side Effects and Efficacy of Neuraxial Opioids in Pregnant Patients at Delivery: A Comprehensive Review
by Sarah Armstrong & Roshan Fernando - 401-407 Dipeptidyl Peptidase (DPP)-4 Inhibitor-Induced Arthritis/Arthralgia: A Review of Clinical Cases
by Annamaria Mascolo & Concetta Rafaniello & Liberata Sportiello & Maurizio Sessa & Daniela Cimmaruta & Francesco Rossi & Annalisa Capuano - 409-419 Safety Profile of Atorvastatin 80 mg: A Meta-Analysis of 17 Randomized Controlled Trials in 21,910 Participants
by Haixia Li & Cailian Wang & Shuo Zhang & Sihao Sun & Ruifei Li & Meijuan Zou & Gang Cheng - 421-432 Evidence of Misclassification of Drug–Event Associations Classified as Gold Standard ‘Negative Controls’ by the Observational Medical Outcomes Partnership (OMOP)
by Manfred Hauben & Jeffrey K. Aronson & Robin E. Ferner - 433-441 An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval
by Tal Lorberbaum & Kevin J. Sampson & Raymond L. Woosley & Robert S. Kass & Nicholas P. Tatonetti - 443-454 Social Media Listening for Routine Post-Marketing Safety Surveillance
by Gregory E. Powell & Harry A. Seifert & Tjark Reblin & Phil J. Burstein & James Blowers & J. Alan Menius & Jeffery L. Painter & Michele Thomas & Carrie E. Pierce & Harold W. Rodriguez & John S. Brownstein & Clark C. Freifeld & Heidi G. Bell & Nabarun Dasgupta - 455-464 Allergy-Like Immediate Reactions with Herbal Medicines: A Retrospective Study Using Data from VigiBase®
by Jitka Pokladnikova & Ronald H. B. Meyboom & Ricarda Meincke & David Niedrig & Stefan Russmann - 465-466 Comment on: “Drug-Induced Hyperglycaemia and Diabetes”
by Jean-Louis Montastruc & Leila Chebane & Haleh Bagheri - 467-467 Authors’ Reply to Montastruc et al.: “Drug-Induced Hyperglycaemia and Diabetes”
by Neila Fathallah & Raoudha Slim & Sofiene Larif & Houssem Hmouda & Chaker Ben Salem
April 2016, Volume 39, Issue 4
- 277-280 Vulnerable Patients and Potential Harms: The Contribution of Observational Research
by Deborah Layton - 281-285 Pharmacovigilance is … Vigilance
by I. Ralph Edwards & Rachida Soulayamani Bencheikh - 287-294 Comparative Safety and Tolerability of Prostacyclins in Pulmonary Hypertension
by Caroline O’Connell & David Amar & Athénaïs Boucly & Laurent Savale & Xavier Jaïs & Marie-Camille Chaumais & David Montani & Marc Humbert & Gérald Simonneau & Olivier Sitbon - 295-305 Quantitative Risk–Benefit Analysis of Probiotic Use for Irritable Bowel Syndrome and Inflammatory Bowel Disease
by William E. Bennett - 307-321 Risk of Seizures Associated with Antidepressant Use in Patients with Depressive Disorder: Follow-up Study with a Nested Case–Control Analysis Using the Clinical Practice Research Datalink
by Marlene Bloechliger & Alessandro Ceschi & Stephan Rüegg & Hugo Kupferschmidt & Stephan Kraehenbuehl & Susan S. Jick & Christoph R. Meier & Michael Bodmer - 323-333 Safety of Intranasal Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) in Children and Adolescents: A Pilot Prospective Cohort Study in England
by Rhian McNaughton & Elizabeth Lynn & Vicki Osborne & Abigail Coughtrie & Deborah Layton & Saad Shakir - 335-345 Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®
by Haggar H. Ampadu & Jarno Hoekman & Marieke L. Bruin & Shanthi N. Pal & Sten Olsson & Daniele Sartori & Hubert G. M. Leufkens & Alexander N. O. Dodoo - 347-354 Sequence Symmetry Analysis as a Signal Detection Tool for Potential Heart Failure Adverse Events in an Administrative Claims Database
by Izyan A. Wahab & Nicole L. Pratt & Lisa Kalisch Ellett & Elizabeth E. Roughead - 355-364 Performance of Stratified and Subgrouped Disproportionality Analyses in Spontaneous Databases
by Suzie Seabroke & Gianmario Candore & Kristina Juhlin & Naashika Quarcoo & Antoni Wisniewski & Ramin Arani & Jeffery Painter & Philip Tregunno & G. Niklas Norén & Jim Slattery - 365-365 Comment on ‘The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project’
by Alain Braillon - 367-368 Authors’ Reply to Alain Braillon’s Comment on “The Contribution of National Spontaneous Reporting Systems to Detect Signals of Torsadogenicity: Issues Emerging from the ARITMO Project”
by Emanuel Raschi & Elisabetta Poluzzi & Francesco Salvo & Ugo Moretti & Fabrizio Ponti - 369-369 Erratum to: Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review
by Rose I. Okonkwo & Anita E. Weidmann & Emmanuel E. Effa
March 2016, Volume 39, Issue 3
- 193-197 Risk of Inflammatory Bowel Disease with Oral Contraceptives and Menopausal Hormone Therapy: Current Evidence and Future Directions
by Hamed Khalili - 199-208 Hepatotoxicity Associated with the Use of Anti-TNF-α Agents
by Joshua B. French & Maurizio Bonacini & Marwan Ghabril & David Foureau & Herbert L. Bonkovsky - 209-218 Renal and Bone Adverse Effects of a Tenofovir-Based Regimen in the Treatment of HIV-Infected Children: A Systematic Review
by Rose I. Okonkwo & Anita E. Weidmann & Emmanuel E. Effa - 219-230 Post-Marketing Benefit–Risk Assessment of Rotavirus Vaccination in Japan: A Simulation and Modelling Analysis
by Edouard Ledent & Alfons Lieftucht & Hubert Buyse & Keiji Sugiyama & Michael Mckenna & Katsiaryna Holl - 231-240 Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter
by Abeed Sarker & Karen O’Connor & Rachel Ginn & Matthew Scotch & Karen Smith & Dan Malone & Graciela Gonzalez - 241-250 Clinicians’ Reports in Electronic Health Records Versus Patients’ Concerns in Social Media: A Pilot Study of Adverse Drug Reactions of Aspirin and Atorvastatin
by Maxim Topaz & Kenneth Lai & Neil Dhopeshwarkar & Diane L. Seger & Roee Sa’adon & Foster Goss & Ronen Rozenblum & Li Zhou